178 related articles for article (PubMed ID: 28564577)
1. Gene therapy and editing: Novel potential treatments for neuronal channelopathies.
Wykes RC; Lignani G
Neuropharmacology; 2018 Apr; 132():108-117. PubMed ID: 28564577
[TBL] [Abstract][Full Text] [Related]
2. Genetics update: Monogenetics, polygene disorders and the quest for modifying genes.
Symonds JD; Zuberi SM
Neuropharmacology; 2018 Apr; 132():3-19. PubMed ID: 29037745
[TBL] [Abstract][Full Text] [Related]
3. In vivo assessment of neurological channelopathies: Application of peripheral nerve excitability studies.
Tomlinson SE; Howells J; Burke D
Neuropharmacology; 2018 Apr; 132():98-107. PubMed ID: 28476643
[TBL] [Abstract][Full Text] [Related]
4. Relevance of tissue specific subunit expression in channelopathies.
Seitter H; Koschak A
Neuropharmacology; 2018 Apr; 132():58-70. PubMed ID: 28669898
[TBL] [Abstract][Full Text] [Related]
5. Muscle channelopathies: recent advances in genetics, pathophysiology and therapy.
Suetterlin K; Männikkö R; Hanna MG
Curr Opin Neurol; 2014 Oct; 27(5):583-90. PubMed ID: 25188014
[TBL] [Abstract][Full Text] [Related]
6. [Autoimmune channelopathies].
Michaud M; Delrieu J; Astudillo L
Rev Med Interne; 2011 Dec; 32(12):742-50. PubMed ID: 22079421
[TBL] [Abstract][Full Text] [Related]
7. Acquired neuronal channelopathies in HIV-associated dementia.
Gelman BB; Soukup VM; Schuenke KW; Keherly MJ; Holzer C; Richey FJ; Lahart CJ
J Neuroimmunol; 2004 Dec; 157(1-2):111-9. PubMed ID: 15579287
[TBL] [Abstract][Full Text] [Related]
8. Post-translational dysfunctions in channelopathies of the nervous system.
Terragni B; Scalmani P; Franceschetti S; Cestèle S; Mantegazza M
Neuropharmacology; 2018 Apr; 132():31-42. PubMed ID: 28571716
[TBL] [Abstract][Full Text] [Related]
9. 'Channeling' therapeutic discovery for epileptic encephalopathy through iPSC technologies.
Simkin D; Ambrosi C; Marshall KA; Williams LA; Eisenberg J; Gharib M; Dempsey GT; George AL; McManus OB; Kiskinis E
Trends Pharmacol Sci; 2022 May; 43(5):392-405. PubMed ID: 35427475
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the pharmacology of neurological gene therapy.
Lowenstein PR; Castro MG
Curr Opin Pharmacol; 2004 Feb; 4(1):91-7. PubMed ID: 15018845
[TBL] [Abstract][Full Text] [Related]
11. A Versatile Clustered Regularly Interspaced Palindromic Repeats Toolbox to Study Neurological Ca
Tsortouktzidis D; Tröscher AR; Schulz H; Opitz T; Schoch S; Becker AJ; van Loo KMJ
Front Mol Neurosci; 2021; 14():667143. PubMed ID: 35069110
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
[TBL] [Abstract][Full Text] [Related]
13. Genetic neurological channelopathies.
Hanna MG
Nat Clin Pract Neurol; 2006 May; 2(5):252-63. PubMed ID: 16932562
[TBL] [Abstract][Full Text] [Related]
14. A Review of Current and Prospective Treatments for Channelopathies, with a Focus on Gene and Protein Therapy.
Sakla M; Breitinger U; Breitinger HG; Mansour S; Nabil Tammam S
Curr Pharm Des; 2023; 29(17):1341-1360. PubMed ID: 37264658
[TBL] [Abstract][Full Text] [Related]
15. Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9.
LaFountaine JS; Fathe K; Smyth HD
Int J Pharm; 2015 Oct; 494(1):180-94. PubMed ID: 26278489
[TBL] [Abstract][Full Text] [Related]
16. Calcium channelopathies in inherited neurological disorders: relevance to drug screening for acquired channel disorders.
Lory P; Mezghrani A
IDrugs; 2010 Jul; 13(7):467-71. PubMed ID: 20582871
[TBL] [Abstract][Full Text] [Related]
17. Autoimmune channelopathies in paraneoplastic neurological syndromes.
Joubert B; Honnorat J
Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2665-76. PubMed ID: 25883091
[TBL] [Abstract][Full Text] [Related]
18. Molecular biology of channelopathies: impact on diagnosis and treatment.
Avanzini G; Franceschetti S; Avoni P; Liguori R
Expert Rev Neurother; 2004 May; 4(3):519-39. PubMed ID: 15853547
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-engineered genome editing for the next generation neurological disease modeling.
Feng W; Liu HK; Kawauchi D
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():459-467. PubMed ID: 28536069
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential.
Oude Blenke E; Evers MJ; Mastrobattista E; van der Oost J
J Control Release; 2016 Dec; 244(Pt B):139-148. PubMed ID: 27498021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
